Clinical trial results:
An exploratory, open-label, single centre, phase II, proof of concept study of gevokizumab treatment in patients with Schnitzler syndrome.

Summary

EudraCT number	2013-002562-39
Trial protocol	NL
Global end of trial date	04 January 2016

Results information

Result version number	v1 (current)
This version publication date	27 April 2017
First version publication date	27 April 2017

Trial information

Trial identification

Sponsor protocol code	CL2-78989-018

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Institut de Recherches Internationales Servier
Sponsor organisation address	50 rue Carnot, Suresnes, France,
Public contact	ITP (Innovative Therapeutic Pole), Institut de Recherches Internationales Servier, +33 15572 4366, clinicaltrials@servier.com
Scientific contact	ITP (Innovative Therapeutic Pole), Institut de Recherches Internationales Servier, +33 15572 4366, clinicaltrials@servier.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 January 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 January 2016
Global end of trial reached?	Yes
Global end of trial date	04 January 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.

Protection of trial subjects:

This study was conducted in accordance with Good Clinical Practice standards, ethical principles stated in the Declaration of Helsinki and applicable regulatory requirements. After the subject has ended his/her participation in the trial, the investigator provided appropriate medication and/or arranged access to appropriate care for the patient.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 3
Worldwide total number of subjects	3
EEA total number of subjects	3

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Males or females aged ≥ 18 years with diagnosis of Schnitzler syndrome at least one year prior, and with active Schnitzler syndrome disease as defined by the presence of at least 2 of 3 clinical criteria (from rash, fever (defined as ≥ 38°C) and bone or arthritis pain) and elevated CRP levels ≥ 30 mg/L, and without clinical signs of tuberculosis.

Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Gevokizumab

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Gevokizumab
Investigational medicinal product code	S78989
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Gevokizumab was administered to 3 patients with starting dose of 60 mg and were to receive maximum dose of 180 mg per 2-week period over a 2-year treatment duration.

Number of subjects in period 1	Gevokizumab
Started	3
Completed	3

Baseline characteristics

Reporting groups	
Reporting group title	Treatment period

Reporting group description: -

Reporting group values	Treatment period	Total	
Number of subjects	3	3	
Age categorical Units: Subjects			
From 65-84 years	3	3	
Gender categorical Units: Subjects			
Female	2	2	
Male	1	1	

End points

End points reporting groups

Reporting group title	Gevokizumab

Reporting group description: -

Primary: no primary criterion

End point title	no primary criterion[1]

End point description:

End point type	Primary

End point timeframe:

As the study was exploratory, no primary endpoint was defined.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: As no primary endpoint was defined for this exploratory study, no statistical analysis was performed.

End point values	Gevokizumab			
Subject group type	Reporting group			
Number of subjects analysed	0[2]			
Units: no unit				

Notes:

[2] - As the study was exploratory, no primary endpoint was defined.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All adverse events which occurred during the treatment period are presented here.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.0

Reporting groups

Reporting group title	Gevokizumab

Reporting group description: -

Serious adverse events	Gevokizumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Gevokizumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)		
Injury, poisoning and procedural complications			
Animal bite			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Fall			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Head injury			

subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Vaccination complication			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Nervous system disorders			
Somnolence			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	2		
Feeling cold			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
General physical health deterioration			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Malaise			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Abdominal pain upper			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	2 / 3 (66.67%)		
occurrences (all)	3		
Dry mouth			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Dyspepsia			

subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Eructation			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Atrophic vulvovaginitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	2		
Epistaxis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Nasal congestion			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	3		
Oropharyngeal pain			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Stress			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Arthralgia			

subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	2		
Back pain			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Metatarsalgia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Musculoskeletal stiffness			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Myalgia			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Osteoarthritis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Infections and infestations			
Bronchitis viral			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Cystitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Gastrointestinal viral infection			
subjects affected / exposed	2 / 3 (66.67%)		
occurrences (all)	2		
Oral herpes			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	4		
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		

Sinusitis			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Upper respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences (all)	1		
Viral upper respiratory tract infection			
subjects affected / exposed	2 / 3 (66.67%)		
occurrences (all)	3		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 July 2014	At inclusion, the starting dose of gevokizumab was increased to 180 mg; as no patient was recruited after the amendment, all included patients received a starting dose of 60 mg as per initial protocol. For on-going patients, the maximum authorised dose was increased up to 180 mg gevokizumab per 2-week period if deemed appropriate by the investigator according to the patient's clinical response over the 2-year treatment period.
21 October 2014	The overall follow-up of patient was extended from 1 to 2 years.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported